日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

HER2DX基因组检测与HER2阳性乳腺癌生物学和病理特征的关联

Sanfeliu, Esther; Martínez-Romero, Anabel; Marín-Aguilera, Mercedes; Cobo, Sandra; González-Farré, Blanca; Hernandez-Illan, Eva; Jares, Pedro; Puig-Butillé, Joan Antón; Muñoz, Montserrat; Gómez-Bravo, Raquel; Tapia, Marta; Tebar, Cristina; Saura, Cristina; Escrivà-de-Romaní, Santiago; Soberino, Jesús; Cortés, Javier; Morales, Serafin; Amillano, Kepa; Paré, Laia; Villagrasa, Patricia; Buckingham, Wesley; Pardo, Francisco; Parker, Joel S; Brasó-Maristany, Fara; Ciruelos, Eva; Sánchez-Bayona, Rodrigo; Martinez-Sáez, Olga; Cejalvo, Juan Miguel; Prat, Aleix

Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane

验证 HER2DX 基因组检测在接受曲妥珠单抗、帕妥珠单抗和紫杉烷一线治疗的 HER2 阳性晚期乳腺癌患者中的应用价值

Kubeczko, Marcin; Cobo, Sandra; Sanchez-Bayona, Rodrigo; Pyciński, Bartłomiej; Soberino, Jesús; Chmielik, Ewa; Sanfeliu, Esther; Rey, Maria; Pardo, Francisco; Aguirre, Angela; Castillo, Oleguer; Lesniak, Aleksandra; Oczko-Wojciechowska, Malgorzata; Carcelero, Esther; Adamo, Barbara; Vidal, Maria; Bergamino, Milana; Maues, Julia; Villacampa, Guillermo; Paré, Laia; Villagrasa, Patricia; Ciruelos, Eva; Prat, Aleix; Jarzab, Michal; Brasó-Maristany, Fara

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab

HER2DX ERBB2 mRNA评分在接受化疗、曲妥珠单抗和帕妥珠单抗一线治疗的HER2阳性晚期乳腺癌患者中的应用

Sánchez-Bayona, Rodrigo; Martínez-Sáez, Olga; Romero-Romero, Denys; Seguí, Elia; Carcelero, Esther; Tolosa, Pablo; Soberino, Jesús; Alva, Manuel; Pascual, Tomás; Lema, Laura; Garcia-Fructuoso, Isabel; Cobos-Fernandez, Maria Angeles; Rey, Maria; Manso, Luis; Aguirre, Angela; Madariaga, Ainhoa; Sirenko, Valeria; González-Deza, Cristina; Blasco, Paula; Mayhua, Astrid; Castillo, Oleguer; Galván, Patricia; Sanfeliu, Esther; Villacampa, Guillermo; Buckingham, Wesley; Marín-Aguilera, Mercedes; Paré, Laia; Villagrasa, Patricia; Perou, Charles M; Maues, Julia; Brasó-Maristany, Fara; Ciruelos, Eva; Prat, Aleix

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy

化疗期间激素依赖性乳腺癌中雌激素受体活性

Chic, Nuria; Schettini, Francesco; Brasó-Maristany, Fara; Sanfeliu, Esther; Adamo, Barbara; Vidal, Maria; Martínez, Débora; Galván, Patricia; González-Farré, Blanca; Cortés, Javier; Gavilá, Joaquín; Saura, Cristina; Oliveira, Mafalda; Pernas, Sònia; Martínez-Sáez, Olga; Soberino, Jesús; Ciruelos, Eva; Carey, Lisa A; Muñoz, Montserrat; Perou, Charles M; Pascual, Tomás; Bellet, Meritxell; Prat, Aleix

Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain

西班牙晚期黑色素瘤患者 Braf 突变频率和临床病理学特征

Jose A Lopez-Martin, Ana Arance Fernández, Juan José Ríos-Martín, Javier Hernández-Losa, Lucía Alós Hernández, Pablo Cerezuela Fuentes, Sebastián Ortiz Reina, Eugenia Ortega Izquierdo, Rosa M Martí, Jesús Soberino García, Berta Ferrer Fábrega, José Luis Rodríguez Peralto; ABSOLUT-BRAF Study Group

Clinical Implications of Extracellular HMGA1 in Breast Cancer

细胞外HMGA1在乳腺癌中的临床意义

Méndez, Olga; Pérez, José; Soberino, Jesus; Racca, Fabricio; Cortés, Javier; Villanueva, Josep

NRAS-mutant melanoma: current challenges and future prospect

NRAS突变型黑色素瘤:当前挑战与未来展望

Muñoz-Couselo, Eva; Adelantado, Ester Zamora; Ortiz, Carolina; García, Jesús Soberino; Perez-Garcia, José

Recent advances in the treatment of melanoma with BRAF and MEK inhibitors

利用BRAF和MEK抑制剂治疗黑色素瘤的最新进展

Muñoz-Couselo, Eva; García, Jesús Soberino; Pérez-García, José Manuel; Cebrián, Vanesa Ortega; Castán, Javier Cortés